Pembrolizumab + Paclitaxel + Carboplatin
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fallopian Tube Cancer
Conditions
Fallopian Tube Cancer, Peritoneum Cancer, Epithelial Ovarian Cancer
Trial Timeline
Dec 22, 2016 → Dec 1, 2022
NCT ID
NCT02834975About Pembrolizumab + Paclitaxel + Carboplatin
Pembrolizumab + Paclitaxel + Carboplatin is a phase 2 stage product being developed by Merck for Fallopian Tube Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT02834975. Target conditions include Fallopian Tube Cancer, Peritoneum Cancer, Epithelial Ovarian Cancer.
What happened to similar drugs?
0 of 4 similar drugs in Fallopian Tube Cancer were approved
Approved (0) Terminated (2) Active (2)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03932409 | Phase 1 | Active |
| NCT02549209 | Phase 2 | Completed |
| NCT02834975 | Phase 2 | Terminated |
Competing Products
20 competing products in Fallopian Tube Cancer